中文(ZH) 阿斯利康据悉同百时美施贵宝洽谈合并

阿斯利康、百时美施贵宝据报探索合并洽谈

作者 PulseAugur 编辑部 · [3 个来源] · 2026-08-02 21:27

据报道，阿斯利康和百时美施贵宝已进行早期合并讨论，但这些讨论不保证会达成交易。这样的合并将创建一个在美国市场拥有重要影响力的制药巨头。百时美施贵宝面临着 Eliquis 和 Opdivo 等关键药物的专利到期，但其新产品有所增长。 AI

排序理由两家主要制药公司之间的合并洽谈。[lever_c_demoted from significant: ic=2 ai=0.1]

AI 生成摘要 · Google Gemini · 来自 3 个来源。我们如何撰写摘要 →

本文如何被排名

Signal score: 0 / 100; Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket: Research; 两家主要制药公司之间的合并洽谈。[lever_c_demoted from significant: ic=2 ai=0.1]
Source corroboration: 3 independent sources; Multiple independent publishers reporting the same story raises confidence that it's real and newsworthy.
Topics: other; Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance: Low; Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness: 65 days old; Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.
Coverage growth since scoring: +1 source(s) since last score; New sources have picked up this story since our last re-score. Score will update on the next scoring pass.

完整方法见我们的编辑标准。

36氪 (36Kr) TIER_1 中文(ZH) · 2026-08-03 07:55

AstraZeneca 计划与 Bristol Myers Squibb 讨论 4000 亿美元的重组计划

英国制药企业阿斯利康（AstraZeneca）正与美国百时美施贵宝公司（Bristol Myers Squibb）就合并事宜进行初步磋商。若交易达成，双方将组建一家估值约4000亿美元的跨国药企，创下全球医药行业并购规模的历史新高。（新浪财经）
36氪 (36Kr) TIER_1 中文(ZH) · 2026-08-02 23:28

AstraZeneca 據報正洽談與 Bristol Myers Squibb 合併

据报道，阿斯利康已同百时美施贵宝洽谈合并事宜。知情人士称，这些商讨发生在近几个月内，且仍有可能告吹。报道并未详述任何潜在交易的具体架构。截至上周五，阿斯利康和百时美施贵宝的市值分别为1960亿英镑（约合2640亿美元）与1330亿美元。（界面）
Fortune TIER_1 English(EN) · Dinesh Nair, Michelle F. Davis, Ashleigh Furlong, Kelly Gilblom, Bloomberg · 2026-08-02 21:27

阿斯利康据称曾探索与百时美施贵宝合并

Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.